Navigating the Frontier of Hematologic Malignancy Therapies (4 of 5 Modules)
This activity provides an overview of key data and ongoing clinical trials investigating the development and use of antibody-drug conjugates (ADC) targeting different myeloid markers for the treatment of pediatric acute myeloid leukemia (AML).
Upon completion of this activity, participants should be better able to:
Full Member, Fred Hutchinson Cancer Center
University of Washington
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources